Company Filing History:
Years Active: 2019
Title: The Innovative Mind of Megan M Breiner
Introduction
Megan M Breiner, based in Memphis, TN, is a notable inventor whose research focuses on therapeutic advancements in pharmacology. With a significant contribution to the field, she holds one patent that addresses critical health challenges, particularly in mental health and neurodegenerative diseases.
Latest Patents
Megan Breiner's patent titled "Negative allosteric modulators of metabotropic glutamate receptor 3" is a groundbreaking development. This invention describes negative allosteric modulators of the metabotropic glutamate receptor 3 (mGlu3), along with pharmaceutical compositions that incorporate these compounds. The methods outlined in her patent offer potential treatments for various conditions, including depression, cognitive disorders, schizophrenia, Alzheimer's disease, and certain cancers.
Career Highlights
Megan is a dedicated researcher at Vanderbilt University, where she has been instrumental in exploring novel therapeutic strategies. Her academic background and commitment to innovation have placed her at the forefront of pharmaceutical research, specifically targeting complex conditions affecting mental faculties and overall health.
Collaborations
Throughout her career, Megan has collaborated with esteemed colleagues such as P Jeffrey Conn and Craig William Lindsley. These partnerships exemplify a collaborative spirit in the scientific community, fostering the exchange of ideas and pushing the boundaries of research in pharmacology.
Conclusion
Megan M Breiner's contributions to science through her patent innovations position her as a significant figure in the field of pharmacology. Her work not only advances scientific knowledge but also holds promise for improving the lives of individuals suffering from debilitating health conditions. As she continues her research at Vanderbilt University, the potential impact of her work remains vast and inspiring.